Matching articles for "Lixiana"
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • February 19, 2024; (Issue 1696)
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • January 8, 2024; (Issue 1693)
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Drugs for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 9, 2019; (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently...
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently updated.
Erenumab (Aimovig) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • June 18, 2018; (Issue 1549)
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive...
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive treatment
of migraine in adults. It is the first drug in its class to
be approved by the FDA.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US guidelines
for treatment of VTE were published in 2016.
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • February 27, 2017; (Issue 1515)
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial...
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial fibrillation
has, however, been associated with an increased
risk of falls, and older patients starting warfarin for
atrial fibrillation have a high rate of hospitalization
for intracranial bleeding. Many practitioners are
reluctant, therefore, to prescribe an oral anticoagulant
for elderly patients who are at high risk for falls.